NCT04620187 2026-02-24Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasDana-Farber Cancer InstitutePhase 2 Recruiting55 enrolled
NCT05408845 2026-01-14Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersNRG OncologyPhase 2 Recruiting146 enrolled